Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000163981 | SCV000214581 | likely benign | Hereditary cancer-predisposing syndrome | 2019-02-09 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV000419264 | SCV000524916 | likely benign | not specified | 2016-02-23 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Color Diagnostics, |
RCV000163981 | SCV000684254 | likely benign | Hereditary cancer-predisposing syndrome | 2017-01-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000636225 | SCV000757657 | likely benign | Familial cancer of breast; Fanconi anemia complementation group J | 2024-05-18 | criteria provided, single submitter | clinical testing | |
KCCC/NGS Laboratory, |
RCV003316013 | SCV004016927 | likely benign | Familial cancer of breast | 2023-07-07 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV003316013 | SCV005403983 | benign | Familial cancer of breast | 2024-09-10 | criteria provided, single submitter | clinical testing | This variant is considered benign. This variant is a silent/synonymous amino acid change and it is not expected to impact splicing. |